MAPT and Alzheimer disease: Despite years of research in AD, drug development and clinical trials targeting Aβ42 or Tau have failed, probably due to the multifactorial nature of AD (Bettens et al., 2013; Jeon et al., 2020; Mehta et al., 2017).